|19.73||-0.1600||-0.80%||Vol 2.22M||1Y Perf -44.07%|
|Apr 13th, 2021 16:00 DELAYED|
|- -||-0.33 -1.67%|
|Target Price||42.00||Analyst Rating||Moderate Buy 1.86|
|Potential %||112.87||Finscreener Ranking||★★ 46.95|
|Insiders Trans % 3/6/12 mo.||-100/-100/-75||Value Ranking||★★ 46.90|
|Insiders Value % 3/6/12 mo.||-100/-100/-65||Growth Ranking||★★★ 54.75|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-58||Income Ranking||— -|
|Market Cap||1.81B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||4.12||Earnings Date||6th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||-0.79|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||7.43M|
|Avg. Monthly Volume||2.62M|
|Avg. Quarterly Volume||1.54M|
FibroGen Inc (NASDAQ: FGEN) stock closed at 19.73 per share at the end of the most recent trading day (a -0.8% change compared to the prior day closing price) with a volume of 2.22M shares and market capitalization of 1.81B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 531 people. FibroGen Inc CEO is Enrique A. Conterno.
The one-year performance of FibroGen Inc stock is -44.07%, while year-to-date (YTD) performance is -46.81%. FGEN stock has a five-year performance of -3.09%. Its 52-week range is between 18.12 and 57.21, which gives FGEN stock a 52-week price range ratio of 4.12%
FibroGen Inc currently has a PE ratio of -8.80, a price-to-book (PB) ratio of 4.08, a price-to-sale (PS) ratio of 11.99, a price to cashflow ratio of 20.70, a PEG ratio of 2.32, a ROA of -21.51%, a ROC of -40.80% and a ROE of -38.47%. The company’s profit margin is -68.65%, its EBITDA margin is -171.40%, and its revenue ttm is $151.92 Million , which makes it $1.66 revenue per share.
Of the last four earnings reports from FibroGen Inc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.79 for the next earnings report. FibroGen Inc’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for FibroGen Inc is Moderate Buy (1.86), with a target price of $42, which is +112.87% compared to the current price. The earnings rating for FibroGen Inc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
FibroGen Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
FibroGen Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 22.25, ATR14 : 3.00, CCI20 : -134.49, Chaikin Money Flow : -0.44, MACD : -6.12, Money Flow Index : 20.89, ROC : -37.01, RSI : 30.52, STOCH (14,3) : 8.94, STOCH RSI : 0.97, UO : 24.75, Williams %R : -91.06), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of FibroGen Inc in the last 12-months were: Elias Kouchakji (Option Excercise at a value of $103 220), Enrique A. Conterno (Buy at a value of $988 882), James A. Schoeneck (Option Excercise at a value of $130 050), K. Peony Yu (Option Excercise at a value of $180 000), K. Peony Yu (Sold 20 052 shares of value $937 686 ), Kalevi Kurkijarvi (Option Excercise at a value of $400 481), Kalevi Kurkijarvi (Sold 17 999 shares of value $814 863 ), Pat Cotroneo (Option Excercise at a value of $922 617), Pat Cotroneo (Sold 47 624 shares of value $2 270 018 ), Roberto Pedro Rosenkranz (Option Excercise at a value of $457 200), Thomas F. Kearns (Option Excercise at a value of $63 000), Thomas F. Kearns (Sold 18 000 shares of value $630 360 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.